PersonGen BioTherapeutics (Suzhou) Co., Ltd. Wins 2026 Forbes China Industry Leading Enterprise Award

Shanghai, China--(Newsfile Corp. - June 8, 2026) - On March 18, 2026, Frost & Sullivan and Forbes China Group jointly hosted the 2026 FORBES CHINA PIONEER INNOVATORS IN INDUSTRY DEVELOPMENT SELECTION GALA BANQUET at the Bulgari Hotel in Shanghai. The awards, co-initiated by Forbes China Group and Frost & Sullivan, feature one main category-the "2026 Forbes China Industry Development Pioneer Innovators"-and three sub-categories: "2026 Forbes China Industry Development Leading Enterprises," "2026 Forbes China Industry Development Innovative Brands," and "2026 Forbes China Industry Development Emerging Analysts." A total of 86 individuals and enterprises received honors. By leveraging its market position and comprehensive strength in the research, development, and industrialization of breakthrough cell therapy technologies, PersonGen BioTherapeutics (Suzhou) Co., Ltd. (hereinafter referred to as "PersonGen" or "the Company") was awarded the title of "2026 Forbes China Industry Development Leading Enterprise."

PersonGen BioTherapeutics (Suzhou) Co., Ltd. is a leading enterprise focused on the R&D and industrialization of breakthrough cell therapy technologies. The company focuses on major indications such as oncology and autoimmune diseases, and has established fully automated eUCAR-γδT™ universal CAR-T platform, GUIDED™ in-vivo CAR-T platform, MNanoNE™ NKCE platform, and exosome preparation platform. With multiple core technology platforms including CAR-T, UCAR-γδT, in-vivo CAR-T, NK cells, and exosomes, it has built an integrated industrial system encompassing R&D, production, and clinical application. Upholding the belief "Benevolence for all, blessings to mankind" the company is dedicated to developing innovative drugs that benefit patients, continuously launching internationally leading First-in-class and Best-in-class cell therapies to serve cancer and autoimmune disease patients.

I. From "No Man's Land" to Global Leader: A 15-Year Expedition of a Chinese CAR-T Company

When PersonGen was registered in Suzhou Industrial Park in 2010, CAR-T therapy was virtually non-existent in China. While most peers focused on B-cell malignancies - an internationally validated path - PersonGen chose a much more arduous road: fully committing its R&D resources to CD7-targeted CAR-T, tackling relapsed or refractory T-lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL), a disease that still lacks effective treatments. The technical difficulty of the CD7 target has deterred most global teams. PersonGen innovatively adopted a non-gene-editing strategy by co-transducing a CD7-CAR lentivirus and a CD7-blocking lentivirus, trapping the CD7 protein in the endoplasmic reticulum and Golgi apparatus of T cells, thereby generating CD7-CAR-T cells that do not express CD7 on the cell surface, and established a new quality control system accordingly. Clinical data from this pipeline strongly validate its value. As the world's first CD7-targeted autologous CAR-T product approved for clinical trials, PA3-17 injection has demonstrated breakthrough "dual-efficacy" potential in Phase I registration trials: an objective response rate (ORR) of 85% and a minimal residual disease (MRD)-negative complete remission rate of 95%. Given that traditional chemotherapy yields a 5-year survival rate of less than 20% for such patients and a long-term survival rate below 10% after relapse, this achievement has opened a new path for patients in a therapeutic desert.

Schreibe Deinen Kommentar